Human to human project service
M34, Inc founded by Prof. Dr. Jude R. Samulski, widely regarded as the “father” of modern gene therapy which is a gene therapy company dedicated to advancing neuro regenerative treatments, have published a groundbreaking retrospective and prospective review on Adeno-Associated Viral (AAV) vectors in the prestigious journal Molecular Therapy.
Among its key highlights, the article for the first time introduces the innovative and pioneering use of AAV libraries in human decedents, a strategy spearheaded by M34, Inc. and known as the Human-to-Human (H2H) Project. Traditional AAV directed evolution strategy had incorporated in vitro cell, ex-vivo organs, rodent species and non-rodent species (such as pig, dog and no human primate). The traditional methods could not cross over the inherent genetic difference between species and complexities such ad epigenetic regulation, splicing mechanism and species/strain specific host factors. H2H approach represents a paradigm shift in vector discovery, with the potential to generate gene therapy tools precisely aligned with human biology.
As the field continues to evolve, such breakthroughs could redefine the treatment landscape for previously incurable diseases, ushering in a new era of hope for patients and families across the globe. Moreover, the H2H platform marks a bold step forward in humanity’s ongoing quest to conquer disease and unlock our biological potential—paving the way not only for enhanced resilience to chronic conditions on Earth but also for addressing the health challenges posed by long-duration space travel, including radiation exposure and mission-related physiological stressors.
M34, Inc had successfully incorporate 9mer randomized peptides into VR-VIII surface loop of AAV5, AAV9 and AAVrh10 vector and administrated into three human decedents and collected over 100 tissue sample from human decedents. Data supports novel AAV variants from each tissue sample across multiple AAV serotype. In the future, we will manufacture and administrated the newly AAV variants into mice, making the first documented case of reverse cross species evolution (from human to mice). This approach will pave the way for more refined AAV vector optimization, accelerating the development of next generation gene therapy.